[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Shire Plc (SHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

November 2018 | 253 pages | ID: SDEE501C3DFEN
GlobalData

US$ 250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Summary

Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to treat patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc (SHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Shire Plc, Medical Devices Deals, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica
Venture Financing
Rani Therapeutics Raises USD53 Million in Venture Financing
OncoResponse Raises Additional USD3 Million in Series A Financing
Promethera Biosciences Raises USD25 Million in Series C Venture Financing
Naurex Raises US$25 Million In Venture Financing
NeuroPhage Pharma Raises US$17 Million In Series D Financing
Lumena Pharma Raises US$45 Million In Series B Financing
Foresight Biotherapeutics Raises US$15 Million In Venture Financing
Suppremol Raises US$20.6 Million In Series D Financing
AesRx Raises US$1.35 Million In Venture Financing
Lumena Pharma Raises US$23 Million In Series A Financing
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing
Ultragenyx Pharma Raises US$75 Million In Series B Financing
Naurex Raises US$38 Million In Series B Financing
ArmaGen Technologies Raises US$17 Million In Series A Financing
bluebird bio Raises US$60 Million In Series D Financing
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing
FerroKin Biosciences Raises US$3 Million In Venture Financing
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing
Partnerships
Pint Pharma Enters into Licensing Agreement with Dyax
Shire and NanoMedSyn Enter into Research Agreement
Dover Life Sciences Enters into Research Collaboration Agreement with Shire
PatientsLikeMe Enters into Agreement with Shire
Generium Forms Joint Venture with Shire
Baxalta Enters into Agreement with Precision Biosciences
Baxalta Enters into Agreement with Symphogen
Novimmune Enters into Research Agreement with Baxalta
Shire Enters into Research Agreement with Foundation Fighting Blindness
Shire Enters into Research Agreement with Cincinnati Children's Hospital
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio
Nimbus Discovery Enters Into Co-Development Agreement With Shire
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics
Shire Enters Into Co-Development Agreement With Boston Children's Hospital For Pediatric Therapies
Shire Enters Into Research Agreement With Fondazione Telethon
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol
Licensing Agreements
Mirum Pharma Enters into Licensing Agreement with Shire
Caladrius Biosciences Enters into Licensing Agreement with Shire
Shire Enters into Licensing Agreement with AB Biosciences
Baxalta Enters into Licensing Agreement with Xenetic Biosciences
Shire Enters into Licensing Agreement with Novimmune
Shire Enters into Licensing Agreement with Parion Sciences for P-321
Neos Therapeutics Enters into Licensing Agreement with Shire
Shire Enters into Licensing Agreement with Pfizer
Shire Enters into Licensing Agreement with ArmaGen for AGT-182
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor
Shire Enters into License agreement with IGAN Biosciences
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002
Dyax Enters Enters into Licensing Agreement with Kadmon
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody
Premacure Amends Licensing Agreement with Insmed
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics
Shire Extends its Licensing Agreement with ArGEN-X
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides
Equity Offering
Shire Plans to Spin Out its Neuroscience Franchise
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares
Baxalta Invests in OncoResponse
Dyax Raises USD230 Million in Public Offering of Shares
Lumena Pharma Withdrawn IPO
Dyax Completes Public Offering Of Shares For US$85 Million
Dyax Completes Public Offering Of Shares For US$69 Million
NPS Pharma Completes Public Offering Of Shares For US$100 Million
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million
Dyax Completes Private Placement Of Shares For US$20.5 Million
Debt Offering
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020
Asset Transactions
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion
Lonza to Acquire Mammalian Manufacturing Site from Shire
RaNA Therapeutics Acquires MRT Platform from Shire
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million
Organogenesis Acquires Dermagraft From Shire For USD300 Million
Acquisition
Takeda Pharma to Acquire Shire
Shire May Acquire Radius Health
Shire Acquires Baxalta for USD32 Billion
Shire Acquires Dyax
Shire Acquires Foresight Biotherapeutics
Actelion Rejects Acquisition Offer from Shire
Baxter International Acquires SuppreMol for USD225 Million
Shire Acquires NPS Pharma for USD5.2 Billion
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million
Baxter Acquires AesRx
Shire Acquires BIKAM Pharma
Shire Acquires Lumena Pharma From RiverVest Venture Partners
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma
AstraZeneca May Acquire Ariad Pharma
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion
Shire Acquires Sarcode Bioscience For up to USD675 Million
Shire Acquires Premacure, Protein Replacement Therapy Developer
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy
AstraZeneca Reportedly Mulls Acquisition of Shire
Shire Acquires Pervasis Therapeutics for USD196 Million
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million
Shire Plc - Key Competitors
Shire Plc - Key Employees
Shire Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Recent Developments
Strategy And Business Planning
Apr 27, 2017: Shire opens new HQ office in Dublin City Centre
Financial Announcements
Nov 01, 2018: Shire delivers product sales growth of 6% and continues to execute against key priorities in Q3 2018
Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
Apr 26, 2018: Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018
Feb 14, 2018: Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017
Oct 27, 2017: Shire Reports Strong Earnings Growth in Q3 2017; Reiterates Full Year Guidance
Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance
May 02, 2017: Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline
Feb 16, 2017: Shire Announces Full Year 2016 Results
Corporate Communications
Jul 25, 2018: Shire announces Director declaration
Mar 22, 2018: Shire Commits to Long-Term Responsibility Goals in 2017 Annual Responsibility Review
Jan 19, 2018: Shire: Directorate Change
Jan 02, 2018: Shire: Director Declaration
Dec 19, 2017: Shire:Director Declaration
Dec 08, 2017: Chief Financial Officer update
Dec 08, 2017: Shire: Chief Financial Officer update
Dec 01, 2017: Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer
Nov 20, 2017: Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors
Aug 21, 2017: Shire Director and Senior Management Changes
Jan 13, 2017: Shire Joins Illinois Biotechnology Innovation Organization as Leadership Sponsor and Adds Shannon Resetich to the Board
Legal and Regulatory
Mar 13, 2018: Shire Applies to Cease to be a Reporting Issuer in Canada
Dec 27, 2017: Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise
Feb 07, 2017: Shire Responds to US Federal Trade Commission Civil Action
Government and Public Interest
Sep 11, 2018: NORD announces ten new rare disease registries, thanks to multi-year grant from Shire
Jan 23, 2018: Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research
Product News
Dec 14, 2017: Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients Through Innovative Personalized Treatment
06/23/2017: Shire to present data on SHP648 at ISTH 2017 to advance the standard of care in Hemophilia
06/21/2018: Shire Announces FDA Approval for Label Expansion of CINRYZE for Prevention of Attacks in Pediatric HAE
05/26/2017: Attention deficit/hyperactivity disorder therapeutic agent ‘INTUNIV Tablets 1 mg/3 mg’ launched in Japan
05/19/2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology
04/26/2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
03/30/2017: INTUNIV (guanfacine hydrochloride prolonged release), a non-stimulant for the treatment of ADHD, receives approval in Japan
03/16/2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
02/24/2017: First hormone replacement therapy for parathyroid disorder
02/15/2018: Shire Announces FDA Acceptance of sBLA for CINRYZE (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
01/24/2017: FDA Grants Approval to Shire for Technology Transfer of CINRYZE (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
01/15/2018: European Medicines Agency: Defect with Buccolam oral syringes
01/06/2017: Xenetic Biosciences Receives $3 Million Milestone Payment from Shire for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
01/03/2018: Xiidra (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease
01/03/2017: Xenetic Biosciences to Present at Biotech Showcase 2017
Product Approvals
Aug 15, 2017: Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe
Jul 07, 2017: Shire Japan Files Hereditary Angioedema Drug Icatibant
Feb 14, 2017: Shire Seeks Approval of Lifitegrast in Canada for the Treatment of Dry Eye Disease in Adults
Clinical Trials
Sep 20, 2017: Shire and Shionogi Announce Positive Topline Results for INTUNIV Evaluated in Phase 3 Clinical Trial in Adults with ADHD
Sep 11, 2017: Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
Other Significant Developments
May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
Jan 08, 2018: Shire announces business update at 36th Annual J.P. Morgan Healthcare Conference
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Shire Plc, Pharmaceuticals & Healthcare, Key Facts, 2017
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Shire Plc, Deals By Therapy Area, 2012 to YTD 2018
Shire Plc, Medical Devices Deals, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica
Rani Therapeutics Raises USD53 Million in Venture Financing
OncoResponse Raises Additional USD3 Million in Series A Financing
Promethera Biosciences Raises USD25 Million in Series C Venture Financing
Naurex Raises US$25 Million In Venture Financing
NeuroPhage Pharma Raises US$17 Million In Series D Financing
Lumena Pharma Raises US$45 Million In Series B Financing
Foresight Biotherapeutics Raises US$15 Million In Venture Financing
Suppremol Raises US$20.6 Million In Series D Financing
AesRx Raises US$1.35 Million In Venture Financing
Lumena Pharma Raises US$23 Million In Series A Financing
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing
Ultragenyx Pharma Raises US$75 Million In Series B Financing
Naurex Raises US$38 Million In Series B Financing
ArmaGen Technologies Raises US$17 Million In Series A Financing
bluebird bio Raises US$60 Million In Series D Financing
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing
FerroKin Biosciences Raises US$3 Million In Venture Financing
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing
Pint Pharma Enters into Licensing Agreement with Dyax
Shire and NanoMedSyn Enter into Research Agreement
Dover Life Sciences Enters into Research Collaboration Agreement with Shire
PatientsLikeMe Enters into Agreement with Shire
Generium Forms Joint Venture with Shire
Baxalta Enters into Agreement with Precision Biosciences
Baxalta Enters into Agreement with Symphogen
Novimmune Enters into Research Agreement with Baxalta
Shire Enters into Research Agreement with Foundation Fighting Blindness
Shire Enters into Research Agreement with Cincinnati Children's Hospital
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio
Nimbus Discovery Enters Into Co-Development Agreement With Shire
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics
Shire Enters Into Co-Development Agreement With Boston Children's Hospital For Pediatric Therapies
Shire Enters Into Research Agreement With Fondazione Telethon
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol
Mirum Pharma Enters into Licensing Agreement with Shire
Caladrius Biosciences Enters into Licensing Agreement with Shire
Shire Enters into Licensing Agreement with AB Biosciences
Baxalta Enters into Licensing Agreement with Xenetic Biosciences
Shire Enters into Licensing Agreement with Novimmune
Shire Enters into Licensing Agreement with Parion Sciences for P-321
Neos Therapeutics Enters into Licensing Agreement with Shire
Shire Enters into Licensing Agreement with Pfizer
Shire Enters into Licensing Agreement with ArmaGen for AGT-182
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor
Shire Enters into License agreement with IGAN Biosciences
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002
Dyax Enters Enters into Licensing Agreement with Kadmon
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody
Premacure Amends Licensing Agreement with Insmed
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics
Shire Extends its Licensing Agreement with ArGEN-X
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides
Shire Plans to Spin Out its Neuroscience Franchise
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares
Baxalta Invests in OncoResponse
Dyax Raises USD230 Million in Public Offering of Shares
Lumena Pharma Withdrawn IPO
Dyax Completes Public Offering Of Shares For US$85 Million
Dyax Completes Public Offering Of Shares For US$69 Million
NPS Pharma Completes Public Offering Of Shares For US$100 Million
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million
Dyax Completes Private Placement Of Shares For US$20.5 Million
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion
Lonza to Acquire Mammalian Manufacturing Site from Shire
RaNA Therapeutics Acquires MRT Platform from Shire
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million
Organogenesis Acquires Dermagraft From Shire For USD300 Million
Takeda Pharma to Acquire Shire
Shire May Acquire Radius Health
Shire Acquires Baxalta for USD32 Billion
Shire Acquires Dyax
Shire Acquires Foresight Biotherapeutics
Actelion Rejects Acquisition Offer from Shire
Baxter International Acquires SuppreMol for USD225 Million
Shire Acquires NPS Pharma for USD5.2 Billion
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million
Baxter Acquires AesRx
Shire Acquires BIKAM Pharma
Shire Acquires Lumena Pharma From RiverVest Venture Partners
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma
AstraZeneca May Acquire Ariad Pharma
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion
Shire Acquires Sarcode Bioscience For up to USD675 Million
Shire Acquires Premacure, Protein Replacement Therapy Developer
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy
AstraZeneca Reportedly Mulls Acquisition of Shire
Shire Acquires Pervasis Therapeutics for USD196 Million
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million
Shire Plc, Key Competitors
Shire Plc, Key Employees
Shire Plc, Other Locations
Shire Plc, Subsidiaries
Shire Plc, Joint Venture

LIST OF FIGURES

Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Shire Plc, Medical Devices Deals, 2012 to YTD 2018 16


More Publications